argenx SE (argenx SE) Change In Payables And Accrued Expense : $0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is argenx SE Change In Payables And Accrued Expense?

argenx SE's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was $0 Mil. It means argenx SE's Accounts Payable & Accrued Expense stayed the same from Sep. 2023 to Dec. 2023 .

argenx SE's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $96 Mil. It means argenx SE's Accounts Payable & Accrued Expense increased by $96 Mil from Dec. 2022 to Dec. 2023 .

argenx SE Change In Payables And Accrued Expense Historical Data

The historical data trend for argenx SE's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Change In Payables And Accrued Expense Chart

argenx SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

53.73

50.54

134.89

0.33

95.60

argenx SE Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

argenx SE Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

argenx SE Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of argenx SE's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (argenx SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.